迈欧莫 2026年季度报告

For the quarterly period ended June 30, 2026or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIESEXCHANGE ACT OF 1934 For the transition period fromto.Commission File Number 001-38109 MYOMO, INC. (Exact name of Registrant as Specified in its Charter) Delaware(State or Other Jurisdiction ofIncorporation or Organization) 45 Blue Sky Drive, Suite 101, Burlington, Massachusetts(Address of principal executive offices) (617) 996-9058 Registrant’s Telephone Number, Including Area Code Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of theSecurities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to filesuch reports), and (2) has been subject to such filing requirements for the past 90 days.Yes:☒No:☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to besubmitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorterperiod that the registrant was required to submit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, asmaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,”“smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer☐Non-accelerated filer☒Emerging growth company☐ Accelerated filer☐Smaller reporting company☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition periodfor complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).Yes☐No☒ At July 31, 2026, the registrant has 39,607,854 shares of common stock, par value $0.0001 per share, outstanding. CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q includes forward-looking statements. Forward-looking statements relate to expectations,beliefs, projections, future plans and strategies, anticipated events or trends and similar matters that are not historical facts. In somecases, you can identify forward-looking statements by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,”“intend,” “may,” “plan,” “potential,” “should,” “will” and “would” or the negatives of these terms or other comparableterminology. You should not place undue reliance on forward looking statements. The cautionary statements set forth in this Quarterly Report onForm 10-Q, including in “Risk Factors” and those contained in our Annual Report on Form 10-K filed with the United StatesSecurities and Exchange Commission on March 9, 2026 and elsewhere, identify important factors which you should consider inevaluating our forward-looking statements. These factors include, among other things: •our ability to achieve or obtain sufficient reimbursement from third-party payers for our products;•our dependence upon external sources for the financing of our operations;•our ability to scale the business to return to positive cash flow from operations;•our revenue concentration with patients who have Medicare Part B insurance coverage;•our ability to continue normal operations and patient interactions without supply chain disruption in order to deliver andfit our custom-fabricated devices;•our marketing and commercialization efforts;•our dependence upon external sources for the financing of our operations, to the extent that we do not achieve ormaintain cash flow breakeven;•our ability to obtain and maintain our strategic collaborations and to realize the intended results of such collaborations;•our ability to effectively execute our business plan and scale up our operations;•our expectations as to our product development programs, including improving our existing products and developing newproducts;•our ability to maintain and grow our reputation and to achieve and maintain the market acceptance of our products;•our expectations as to our clinical research program and clinical results;•our ability to maintain adequate protection of our intellectual property and to avoid violation of the intellectual propertyrights of others;•our ability to gain and maintain regulatory approvals;•our ability to compete and succeed in a highly competitive and evolving industry;•general market, economic, environmental and social factors that may affect the evaluation, fitting, delivery and sale ofour products to patients; and•other risks and uncertainties, including those listed under the caption “Risk Factors” in this Quarterly Report on Form 10-Q. Although the forw